VK2735 clinical trials
Also written VK2735.
How each study uses VK2735 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VK2735 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test VK2735, phase 3 first.
- Jul 2027VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Phase 3 · Viking Therapeutics, Inc.
- Jul 2027VK2735 for Weight Management Phase 3Phase 3 · Viking Therapeutics, Inc.
- May 2027A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesPhase 1 · Viking Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses VK2735 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)RecruitingPhase 3Viking Therapeutics, Inc.NCT07868939Written as VK2735 Oral
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)RecruitingPhase 3Viking Therapeutics, Inc.NCT07868835Written as VK2735
- A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesRecruitingPhase 1Viking Therapeutics, Inc.NCT07838740Written as VK2735 Drug
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Active, not recruitingPhase 3Viking Therapeutics, Inc.NCT07104383Written as VK2735
- VK2735 for Weight Management Phase 3Active, not recruitingPhase 3Viking Therapeutics, Inc.NCT07104500Written as VK2735
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)CompletedPhase 2Viking Therapeutics, Inc.NCT06828055Written as VK2735
- Phase 1 Study to Evaluate the Safety and Tolerability of VK2735CompletedPhase 1Viking Therapeutics, Inc.NCT05203237Written as VK2735
- VK2735 for Weight Management Phase 2CompletedPhase 2Viking Therapeutics, Inc.NCT06068946Written as VK2735
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Nov 16, 2026NCT07868835
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Nov 16, 2026NCT07868939